Cargando…
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
BACKGROUND: Trastuzumab treatment for women with HER2-positive breast cancer (BC) resulted in the significant improvement of both relapse free survival (RFS) and overall survival (OS). However, many women who are classified as HER2-positive do not respond. Many studies have focused on the role of so...
Autores principales: | Toomey, Sinead, Madden, Stephen F., Furney, Simon J., Fan, Yue, McCormack, Mark, Stapleton, Carragh, Cremona, Mattia, Cavalleri, Gianpiero L., Milewska, Malgorzata, Elster, Naomi, Carr, Aoife, Fay, Joanna, Kay, Elaine W., Kennedy, Susan, Crown, John, Gallagher, William M., Hennessy, Bryan T., Eustace, Alex J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342757/ https://www.ncbi.nlm.nih.gov/pubmed/27776352 http://dx.doi.org/10.18632/oncotarget.12782 |
Ejemplares similares
-
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018) -
Frequency, impact and a preclinical study of novel
ERBB gene family mutations in HER2-positive breast
cancer
por: Elster, Naomi, et al.
Publicado: (2018) -
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018) -
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017) -
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)